Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-thioguanine registry in 6-TG-naive inflammatory bowel disease patients
NL-OMON21729Active, not recruiting
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tioguanine in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease, sponsored by None. Primary endpoint: Maintenance of remission at 12 months. Started Jul 2015; status: active, not recruiting.
02
Drugs
tioguanine
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON21729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21729.